Key facts
- VERIGRAFT’s last known valuation is $29.7M (Mar 2025).
- It has raised $25.3M; the latest was Later Stage VC ($12.1M) in Mar 2026.
- Notable investors include Eurostars, Horizon 2020, ID Ventures (South Korea), Scientia Ventures.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for VERIGRAFT
- ·The full record, as it builds
Funding rounds
No funding rounds for VERIGRAFT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VERIGRAFT
Developer of personalized tissue engineered human grafts designed for transplantation and tissue replacement purposes. The company's platform applies decellularised donated human tissues combined with patient-derived cells, standardized GMP compliant manufacturing processes, immune compatibility matching, and quality controlled biological scaffolds to produce individualized veins, arteries, and other soft tissues, enabling hospitals, transplant centers, and clinical researchers to address vascular and tissue repair needs while reducing immune rejection risk and long-term dependence on immunosuppressive therapies.
- Sector
- Healthcare
- HQ
- Gothenburg, Sweden
- Founded
- 2004
- Employees
- 18
- Website
- verigraft.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
VERIGRAFT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VERIGRAFT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VERIGRAFT in its N-PORT filings yet. We sweep new filings monthly.